Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults

NCT06036602 is registered in ClinicalTrials.gov with Albert B. Sabin Vaccine Institute as lead sponsor.

NCT NCT06036602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06036602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Lead sponsor
Albert B. Sabin Vaccine Institute
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2024
Completion date
November 8, 2025
Enrollment
125 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ebola sudan virus disease